Earnings ·
Eupraxia reports $15.2M Q3 loss and reaches 120-patient enrollment in RESOLVE trial
EPRXEupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals reported a net loss of $15.2 million for the third quarter ended September 30, 2026, compared to a $6.4 million loss in the prior-year period. The increase was driven by higher research and development costs from doubling the Phase 2b RESOLVE trial size and increased general and administrative expenses. As of September 30, the company held $75.2 million in cash and equivalents plus $51.2 million in short-term investments, providing a runway into the second half of 2028. Operationally, Eupraxia announced it reached its target enrollment of 120 patients in the placebo-controlled blinded Phase 2b portion of the RESOLVE trial evaluating EP-104GI for eosinophilic esophagitis (EoE). Interim results from this phase are expected in December 2026. The company is a clinical-stage biotechnology firm developing locally delivered, extended-release products using its proprietary Diffusphere technology.